Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Geron enters 2026 as a newly minted commercial hematology company with one marketed product, RYTELO (imetelstat), and a late-stage program that could pivot the story from niche LR-MDS anemia to broader myelofibrosis survival if the Phase 3 IMpactMF study delivers.
Over the last few weeks ImmunityBio has done pretty much everything a biotech can do to light up screens: big revenue jump, new regulatory approvals and sexy cell-therapy data. The stock has reacted exactly the way you would expect in a heavily shorted name – vertical move, news sites still talking about it days later, social media on fire.
In this piece we are going to do something boring but necessary: stack all the verifiable positives (with links), then put them next to the very real risks. Only at the end we’ll talk about the “everybody is still pushing this story” part and why that’s exactly the moment when you want to cool your head.
AI platform targeting highly regulated clients. Q4 2025 marked a “turning point”: a top-10 pharma engagement project, the Skye Salud sovereign healthcare JV in Mexico, and a first step in cleaning up a heavily diluted balance sheet.
Novocure’s Phase 3 TRIDENT study did not show a statistically significant overall-survival advantage for starting Tumor Treating Fields earlier during chemoradiation in newly diagnosed glioblastoma. The result is not a collapse of the TTFields platform, but it is a serious reset for the near-term narrative: the company must now prove that its growth story can be carried by commercial execution, pancreatic cancer, brain metastases from NSCLC, and the next wave of combination trials.
Atossa Therapeutics is a small-cap, clinical-stage biotech built around a single platform asset, the oral selective estrogen receptor modulator (SERM) (Z)-endoxifen. Until 2025 the investment story was mostly about breast cancer treatment and risk reduction, but in the last few months the company has opened a new front in Duchenne muscular dystrophy (DMD).
The FDA has approved an extension of the indicated duration of Nexplanon (etonogestrel implant) up to 5 years for the prevention of pregnancy, versus the previous 3-year label. Nexplanon is the flagship long-acting reversible contraception (LARC) product of Organon and one of the core pillars of its Women’s Health division.
eek of 12–17 January 2026 – a structured overview of what is really moving markets, geopolitical risk and the most talked-about tickers.
Why this NVAX update after JPM 2026
Novavax is a rare case where the narrative matters almost as much as the numbers. The company went from “late Covid vaccine laggard” to “maybe dead”, then back to life thanks to a sequence of deals and restructurings. The 44th J.P. Morgan Healthcare Conference was the moment where CEO John Jacobs tried to lock in a new story: Novavax as a lean, partner-driven, Matrix-M platform company with a visible (not guaranteed) path to sustainability.
Why it is a “stock of the moment”
ONDS is one of the most closely watched names in the community: explosive rally, very strong narrative around Israel/defense, and now an Investor Day that pushes the bar even higher with 2026 guidance and very aggressive 5-year targets. It is a classic case where enthusiasm and risk coexist: great to follow, dangerous to underestimate.
Rezolve AI (RZLV) – Agentic commerce hype vs. fragile fundamentals
Generative-AI retail platform guiding to explosive revenue growth, but starting from tiny 2024 sales, heavy losses and limited cash.
This article is the natural continuation of the analysis published on January 3, 2026 on Merlintrader. Since then, POET has gone through a very busy few weeks: a strong share price move, intense options activity, fresh buzz around AI photonics, the long shadow of Marvell’s acquisition of Celestial AI, and a stream of unconfirmed rumours in retail communities.
igh-risk non-muscle-invasive bladder cancer after failure of BCG has become one of the hottest oncology niches of 2025–2026. ImmunityBio with ANKTIVA is already on the market, while CG Oncology and enGene are coming fast with late-stage programs. This report compares mechanisms, clinical data, timelines and sentiment, so traders can look beyond the single name that is dominating the headlines in these weeks.
Achondroplasia already has one FDA-approved therapy on the market (BioMarin’s Voxzogo), so TransCon CNP is a “second entrant” story. That means the regulatory decision matters, but so will positioning, differentiation, and adoption post-approval.
Jeffs’ Brands Ltd is a tiny Israeli micro-cap originally built around a data-driven Amazon FBA portfolio. That legacy business is still there: roughly $13.7M revenue in FY2024 against a net loss of about $7.8M, with a very small equity value and high operating leverage. The last twelve months have been brutal for long-term holders, with a price trajectory closer to a ski slope than a growth story.
Daily Hit on Ocular Therapeutix after the latest spike on renewed takeover chatter and ahead of the 52-week phase 3 SOL-1 readout for AXPAXLI (suprachoroidal axitinib). Cash-heavy balance sheet, a single pivotal asset at the centre of the story, and a market now trying to price both M&A optionality and binary clinical risk.
Defense & Industrial AI – 2026 Inflection Plan
Embedded AI autonomy for defense and industrial operators (IQ 2.0, UAV swarms, advanced avionics, precision manufacturing). Analysis updated after Needham 2026 & new revenue guidance.
Deep-dive update on ImmunityBio after the Saudi Food and Drug Authority granted approval to ANKTIVA + BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, on top of existing approvals in the U.S., U.K. and conditional approval in the EU. Focus on the non-muscle invasive bladder cancer franchise, commercial trajectory, balance sheet and the next catalysts around QUILT-3.032 and QUILT-2.005.
Short update on Omeros after the FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA, the start of the U.S. launch and the analyst upgrades published in early January 2026. For the full story, background and detailed scenarios, see the main OMER reports on Merlintrader.
Short update on VK2735 after the Phase 2 VENTURE data were published in the journal Obesity and after CEO Brian Lian’s comments at the J.P. Morgan Healthcare Conference 2026. For the full story, fundamentals and detailed scenarios, see the main VKTX report on Merlintrader.
BriaCell Therapeutics (BCTX) is the definition of a high-beta biotech: a tiny, heavily dilutive, clinical-stage immuno-oncology company with a real science story, now colliding head-on with a brutal funding reality. On January 13, 2026, the company reported an 11-month sustained complete resolution of a lung metastasis in a 78-year-old metastatic breast cancer patient treated with Bria-OTS in Phase 1/2a – no dose-limiting toxicities, stable disease at other sites, Phase 1 completed and Phase 2a combo underway. That headline sent the stock vertical.
Within hours, BriaCell followed up with a $30M best-efforts public unit offering at $5.59 per unit, each unit including one common share (or pre-funded) + one listed warrant at $6.93 (BCTXL) with five-year maturity. The market’s response: a pre-market gap down to ~$5.0, more than -50% vs the prior close at $10.92, and a reset of the whole technical picture.